A carregar...
Development of Novel Anti-Cd20 Monoclonal Antibodies and Modulation in Cd20 Levels on Cell Surface: Looking to Improve Immunotherapy Response
Rituximab has been revolutionized and validated CD20 targeting monoclonal antibody. Although, it is widely used for lymphoma therapy and many patients have been benefited. However significant numbers of patients are refractory or developed resistance to current therapies due to low level of CD20 exp...
Na minha lista:
| Publicado no: | J Cancer Sci Ther |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4939752/ https://ncbi.nlm.nih.gov/pubmed/27413424 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4172/1948-5956.1000373 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|